Board-Certified Oncologist in Hematology in Puyallup, WA
“While listening to the goals and understanding of each person, I educate, review treatment options, provide guidance, and support individual decisions.” – Andrea Veatch, MD
Dr. Andrea Veatch is board-certified in Medical Oncology, Hematology, and Hospice and Palliative Care. She has an interest and focus in thoracic and head/neck cancers as well as other cancer types.
Dr. Veatch earned her medical degree from the University of Minnesota and completed her Internal Medicine residency at Mt. Sinai Medical Center in New York. Dr. Veatch completed her Fellowship in Medical Oncology and Hematology at the Fred Hutchinson Cancer Center, where she also was a researcher until she joined NWMS in 2004.
Dr. Veatch worked in basic science medical research throughout her education and training and continues to participate in clinical research and clinical trials.
Medical School: University of Minnesota
Residency: Mt. Sinai Medical Center
Fellowship: Fred Hutchinson Cancer Research Center and University of Washington
Board Certification: Medical Oncology, Hematology, Hospice and Palliative Care
Peer-Reviewed Publications:
- Reck M, Dziadziuszko R, Sugawara S, et al., Veatch A, et al. Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the phase III IMpower133 study and the phase III IMbrella A extension study. Lung Cancer. Oct 2024; 196: 107924. DOI: 10.1016/j.lungcan.2024.107924
- Liu SV, Dziadziuszko R, Sugawara S, et al., Veatch A, et al. OA01.04 Five-year survival in patients with ES-SCLC treated with atezolizumab in IMpower133: IMbrella A extension study results. J Thorac Oncol. Nov 2023; 18(11): S44-S45. DOI: 10.1016/j.jtho.2023.09.025
- Rich P, Mitchell RB, Schaefer E, et al., Veatch A, et al. Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer. J Immunother Cancer. Oct 27, 2021; 9(10): e002989. DOI: 10.1136/jitc-2021-002989